Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthma

Abstract

This study demonstrates that add-on omalizumab therapy is cost-effective in patients with severe persistent allergic asthma.

Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model

“…The analysis by Brown et al does use the unit of cost per QALY but has other shortcomings. Although the study used for analysis includes a total of 206 subjects in the omalizumab group, the analysis by Brown et al only includes the 68 subjects who responded to omalizumab, defined as having a 0.5-point or greater improvement in the Mini-AQLQ (Brown et al 16 and Ayres et al 46 ). Thus this analysis is a narrow analysis and does not represent the real-world setting in which omalizumab response cannot be predicted before treatment.…”

“…They concluded that omalizumab is not cost-effective. Another cost-effectiveness analysis by Brown et al 16 suggested that omalizumab is cost-effective; however, this analysis was based on a small open-label trial, and the analysis was limited to subjects who were responsive to omalizumab. This creates a strong bias in favor of omalizumab.…”

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

“…The cost-effectiveness of anti-IgE has been appreciated for its indication in severe asthma (1742,1743) but not for rhinitis.…”

Health economics of asthma: assessing the value of asthma interventions

“…Eight studies compared monotherapy vs monotherapy (38,41,42,45,46,51,56,58). Four studies compared add-on omalizumab vs usual care (39,47,57,60). There was one study over the time period that considered the costs of reliever therapies, but since no health outcome was reported this study was excluded (62).…”